MedTrace Logo

Effect of Early Systemic Stabilization Therapy on Recent Onset Vitiligo

NCT05037981 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2021-09-08

No results posted yet for this study

Summary

Vitiligo is a distressing disorder of depigmentation. In spite of multiple successful therapeutic regimens, disease relapse remains a challenge to patients and physicians. Most guidelines consider systemic treatments only in rapidly progressive disease with wider surface areas. This delay in halting the immune attack, may give the chance for further disease progression as well as establishment of resident memory T cell population predisposing to future disease relapses. The aim of this study was to assess the ability of early systemic therapy of localized (\<2% BSA), recent onset (\<6 months) vitiligo to control disease activity and minimize the possibility of recurrence.

Conditions

  • Vitiligo

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Samia Esmat, MD · Cairo University

  • Rania Mogawer, MD · Cairo University

  • Dalia Bassiony, MD · Cairo University

  • Suzan Shalaby, MD · Cairo University

  • Rehab Hegazy, MD · Cairo University

  • Nanis Ragab, MD · Cairo University

  • Sarah Ibrahim · Cairo University

Eligibility

Min Age
6 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-10
Primary Completion
2021-08-10
Completion
2021-08-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05037981 on ClinicalTrials.gov